2014 Top Stocks Market, Best Stocks Investment In 2014, Top Stocks For 2014: 5 Best Stocks In 2014

The political uproar from the debt-ceiling negotiations has resulted in high volatility and heavy selling in the past week. But despite the uncertainties, along with an economic slowdown in Europe and the United States, stocks are still confined to a trading range that began early this year.

But offsetting the uncertainties is the fact that with more than three-quarters of all companies reporting earnings, almost three-quarters of them have exceeded Q2 earnings estimates. Thus, it appears that the current trading range will be maintained. Patient investors should use the current pullback as an opportunity to acquire undervalued securities.

Here are your top stocks to buy for August:

5 Best Stocks In 2014:Exceed Company Ltd. (EDS)

Exceed Company Ltd. engages in the design, development, and wholesale of footwear, apparel, and accessories in the People?s Republic of China. The company offers its products under the Xidelong brand name for sports and leisure applications to customers aging between 15 to 35 years. Its products include running, leisure, basketball, skateboarding, canvas, tennis, and outdoor footwear; apparel primarily consisting of sports tops, pants, jackets, track suits, and coats; accessories, such as bags, socks, hats, and caps. The company distributes its products primarily through Xidelong retail stores that are operated by independent third-party distributors and retailers over which the company has limited control. Exceed Company Ltd. is based in Central, Hong Kong.

5 Best Stocks In 2014:Cinemark Holdings Inc (CNK)

Cinemark Holdings, Inc. and its subsidiaries engage in the motion picture exhibition business. As of June 30, 2011, it operated 436 theatres with 4,983 screens in 39 states of the United States, as well as in Brazil, Mexico, and 11 other Latin American countries. The company is headquartered in Plano, Texas.

Advisors' Opinion:

By Jeff Reeves At 2011-10-21
Cinemark Holdings Inc. (NYSE: CNK) owns movies theaters across the United States and Latin America, with a total of about 5,000 screens in America alone.

Current Yield: 4% (84 cents a share annually)

Dividend History: In June 2010, Cinemark paid a quarterly dividend of 18 cents a share. This July, it will pay 21 cents, for a nearly 17% increase.

Dividend Outlook: According to Bloomberg, the three-year expected dividend growth rate of CNK is 2.5%.

Recent Performance: Cinemark has surged over 20% so far in 2011, more than doubling the market. It is approaching a new 52-week high as of this publication.

Strong Outlook for Shares: Cinemark has seen improving revenue each year since 2007, connecting with movie-goers despite the recession. That’s in part because of growth and acquisitions — most recently it plans to buy a 12-screen cinema in South Carolina. The movie industry may not be booming right now, but CNK could cash in big time when box office receipts improve thanks to its growth over the last few years.

5 Best Stocks In 2014:Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, produces, and markets generic drugs; and proprietary branded pharmaceuticals in various therapeutic categories and active pharmaceutical ingredients worldwide. The company?s provides generic drug portfolio of approximately 1,450 molecules and a direct presence in 60 countries. It offers generic pharmaceutical products in a range of dosage forms, such as tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The company sells its generic injectable products to hospitals, clinics, and other institutional channels, primarily in the United States and Europe, as well as in Latin America and eastern Europe. Its branded products include Copaxone to treat multiple sclerosis; and Azilect to treat Parkinson?s disease, as well as biosimilars, respiratory, and women?s health products. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

5 Best Stocks In 2014:Savient Pharmaceuticals Inc (SVNT)

Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It sells its products directly to drug wholesalers. The company, formerly known as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in June 2003. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in East Brunswick, New Jersey.

Related Articles: